Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or greater~2. Diagnosis of suspected thrombotic thrombocytopenic purpura (TTP)~   1. Platelet count of \< 80,000 for newly diagnosed patients and \< 120,000 for relapsed patients~  2. Microangiopathic hemolytic anemia with RBC fragmentation~  3. LDH \>1 x ULN~3. Subjects who will receive treatment for TTP with plasma exchange~4. Subjects who have not started the 5th plasma exchange~5. Plasma ADAMTS13 activity \<10%~Exclusion Criteria:~1. Treatment for TTP within the past 2 months~2. Severe active infection indicated by sepsis (requirement for pressors with or without positive blood cultures) or clinical evidence of enteric infection with E. coli O157:H7 or related organism~3. Currently under treatment for cancer (subjects with localized skin carcinoma will be accepted)~4. Microangiopathic hemolytic anemia due to a mechanical heart valve~5. Severe hypertension, as defined by systolic BP \>180 AND diastolic BP \>120, or papilledema~6. Organ or stem cell transplant~7. Use of calcineurin inhibitors (sirolimus, tacrolimus, cyclosporin A) within 6 months prior to diagnosis of TTP~8. Disseminated intravascular coagulation as defined by:~   a. INR \>2.0 (unrelated to anticoagulation, unresponsive to Vitamin K) or b. Fibrinogen \<100 mg/dl~9. Pregnancy~10. Known congenital TTP.~11. Rituximab within the previous year.~12. HIV history or positive serology~13. History of hepatitis B or positive serology for HBsAg or Anti-HBc~14. Persistent or unexplained platelet count below 150,000/μL within 3 months of current TTP presentation~15. Hypersensitivities or allergies to murine and/or humanized antibodies~16. Current participation in trials of investigational therapies or devices, other than central catheters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose rituximab (Type: EXPERIMENTAL): this is a single-arm trial

Based on this trial design, predict the completion outcome and termination type (if applicable).